DOCSLIB.ORG

Pelvic Exenteration As Ultimate Ratio for Gynecologic Cancers: Single‑Center Analyses of 37 Cases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pelvic Exenteration As Ultimate Ratio for Gynecologic Cancers: Single‑Center Analyses of 37 Cases Archives of Gynecology and Obstetrics (2019) 300:161–168 https://doi.org/10.1007/s00404-019-05154-4 GYNECOLOGIC ONCOLOGY Pelvic exenteration as ultimate ratio for gynecologic cancers: single‑center analyses of 37 cases N. de Gregorio1 · A. de Gregorio1 · F. Ebner2 · T. W. P. Friedl1 · J. Huober1 · R. Hefty3 · M. Wittau4 · W. Janni1 · P. Widschwendter1 Received: 5 February 2019 / Accepted: 5 April 2019 / Published online: 22 April 2019 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Background Pelvic exenterations are a last resort procedure for advanced gynecologic malignancies with elevated risks in terms of patients’ morbidity. Methods This single-center analysis reports surgical details, outcome and survival of all patients treated with exenteration for non-ovarian gynecologic malignancies at our university hospital during a 13-year time period. We collected data regarding patients and tumor characteristics, surgical procedures, peri- and postoperative management, transfusions, complications, and analyzed the impact on survival outcomes. Results We identifed 37 patients between 2005 and 2013 with primary or relapsed cervical cancer (59.5%), vulvar cancer (24.3%) or endometrial cancer (16.2%). Median age was 60 years and most patients (73%) had squamous cell carcinomas. Median progression-free survival was 26.2 months and median overall survival was 49.9 months. The 5-year survival rates were 34.4% for progression-free survival and 46.4% for overall survival. There were no signifcant diferences in progres- sion-free survival and overall survival with regard to disease entity. Patients with tumor at the resection margins (R1) had a nearly signifcantly worse progression-free survival (median: 28.5 vs. 7.3 months, HR 2.59, 95% CI 0.98–6.88, p = 0.056) and a signifcantly worse overall survival (median: not reached vs. 10.9 months, HR 4.04, 95% CI 1.40–11.64, p = 0.010) compared to patients with complete tumor resection (R0). In addition, patients without lymphovascular space invasion had a signifcantly better progression-free survival (p = 0.017) and overall survival (p = 0.034) then patients with lymphovascular space invasion. We observed complications in 14 patients (37.8%), 10 of those were classifed as Clavien–Dindo 3 or 4. There was a trend to worse progression-free survival in patients that sufered complications (p = 0.052). Median total amount of transfused blood products was 4 (range 0–20). Conclusion Pelvic exenteration is a procedure that provides substantial progression-free survival and overall survival improvement and—in selected patients—can even achieve cure in otherwise hopeless clinical situations. Patients need to be ofered earnest counseling for sufcient informed consent with realistic expectations what to expect. Keywords Pelvic exenteration · Advanced gynecologic malignancy · Cervical cancer · Endometrial cancer · Vulvar cancer Introduction * N. de Gregorio For almost 50 years, pelvic exenteration has been used as a [email protected] last resort for patients with advanced or relapsed gyneco- logic malignancies. Depending on the surgical extend an 1 Department of Obstetrics and Gynecology, University anterior, posterior or complete exenteration is diferentiated. of Ulm, Prittwitzstr. 43, 89075 Ulm, Germany The anterior exenteration is defned as the removal of the 2 Department of Obstetrics and Gynecology, Amper Hospital uterus, tubes, ovaries, parametrium, vagina, urinary bladder Dachau, Dachau, Germany and urethra. In case of a posterior exenteration, the bladder 3 Department of Urology, Klinikum Heidenheim, and urethrae are spared and the rectum is removed instead. Heidenheim an der Brenz, Germany A complete exenteration comprises all of those organs. A 4 Department of General Surgery, University of Ulm, Ulm, further variation is the removal of the perineal compartment, Germany Vol.:(0123456789)1 3 162 Archives of Gynecology and Obstetrics (2019) 300:161–168 mostly performed in cases of a relapsed vulvar or vaginal Data regarding age, weight, body height, initial tumor carcinoma. Here, myocutaneus skin faps are used to recon- stage, tumor type and subtype, grade, time interval since last struct pelvic foor defects in the perineal region. treatment and staging procedures were collected; in addition, Survival rates after exenteration tend to be poor due to the the histological factors tumor size, vascular and lymphovas- often advanced stages of the diseases, but sometimes even cular space invasion and resection margin (negative/posi- cure can be achieved in case of a complete resection with tive and location of residual tumor) were documented. To be tumor-free margins. Ultraradical surgical concepts like the able to comprehensively assess the surgical procedures, we lateral extended endopelvine resection (LEER) have been collected data on all previous lines of treatment, time in the introduced to improve complete resection rates in the last operating theater, methods of bowel and bladder reconstruc- years [1]. A LEER procedure extends the resection margin tion, intra- and postoperative complications (classifed after to the osseous pelvic side wall which includes a resection Clavien–Dindo) [6], progression-free and overall survival, of the internal iliac vessels and their branches. Even in very estimated blood loss, number of transfused blood product experienced centers, those procedures still tend to be risky (thrombocytes, frozen–fresh plasma, packed red blood cells), with high rates of perioperative morbidity (> 50%) and even total length of hospital stay and any adjuvant treatment. mortality (up to 5%) [2]. In addition, the patients’ quality of All data were extracted from the available archived patient’s life has been reported to be signifcantly reduced within the documents and subsequently anonymized. All procedures frst 3 months after the procedure [3]. performed in this study involving human participants were In spite of an overall decreasing incidence, relapsed cer- in accordance with the ethical standards of the institutional vical cancer accounts for the majority of cases in recently committee. Ethical approval of the ethics committee of the published studies regarding exenterative surgery, followed University Ulm was given (73/18). by endometrial cancer and infrequently vulvar or vaginal carcinomas [4]. Even for colorectal carcinomas, exentera- Statistical analysis tion is used as a salvage procedure, with lower morbidity compared to gynecologic malignomas (50% vs. 75%) and at Categorical variables are summarized and described using the same time signifcantly improved 5 year overall survival absolute and relative frequencies, while ordinal and continu- (92.9% vs. 58%) [5]. ous variables are described using medians, interquartile ranges Widely accepted patient selection criteria for an exen- and ranges. As the data distribution of most of the continuous teration are the possibility of complete resection, no dis- variables was signifcantly diferent from normal distribu- tant metastases, unavailability of less radical alternatives, tion (Shapiro–Wilk test), non-parametric statistical tests were willingness of the patient to accept the drastic body modi- used for all analyses presented here. Correlation tests were fcations and patients’ general condition that allow a proce- performed using Spearman’s rank correlation coefcient r. dure of this magnitude. While a multidisciplinary approach Progression-free survival (without deaths) and overall survival (including lower GI surgeons and urologists) is mandatory, data were analyzed using the Kaplan–Meier method and sum- this procedure also requires a very experienced gynecologic marized using medians, 95% confdence limits (95% CI) and surgeon and an adequate institutional infrastructure in terms Kaplan–Meier survival plots. All time-to-event intervals were of a blood bank and an intensive care unit. measured from the date of surgery to the date of the event. If This study reports the institutional experience of the no event was documented, the data were censored at the date department of obstetrics and gynecology of the University of the last adequate follow-up. Between group comparisons Hospital Ulm with the conduction of exenterations over a of progression-free survival and overall survival were per- 12-year time interval. formed with the log-rank test and hazard ratios (HR) were calculated based on univariable cox regression models. All statistical analyses were performed using the SPSS statistical software package, version 24 (IBM, New York, NY, USA). All Materials and methods statistical tests were two-sided, and p values below 0.05 were considered signifcant (no adjustment of signifcance levels Patient characteristics and variable selection for multiple testing). Data from all patients having the documented procedures “Exenteration” and/or “LEER” at our Department of Gynecology and Obstetrics at the University Hospital Ulm between January 1st, 2005 and February 28 th, 2018 were ret- rospectively reviewed. We identifed 37 cases with complete datasets for further analysis. 1 3 Archives of Gynecology and Obstetrics (2019) 300:161–168 163 Results Table 1 Baseline characteristics of 37 women with exenteration or LEER Patient characteristics Variable Age (years) The median age in the patients’ collective was 60 years, Median 60 ranging from 24 to 83 years, and median BMI was 23.9 kg/ Interquartile range 47.5–67.5 2 2 m (range 16.2–46.7 kg/m ). 59.5% of patients had a cervical Range 24–83 carcinoma, followed
Load more

Recommended publications
  • Curative Pelvic Exenteration for Recurrent Cervical Carcinoma in the Era of Concurrent Chemotherapy and Radiation Therapy
    Available online at www.sciencedirect.com ScienceDirect EJSO xx (2015) 1e11 www.ejso.com Review Curative pelvic exenteration for recurrent cervical carcinoma in the era of concurrent chemotherapy and radiation therapy. A systematic review H. Sardain a,b, V. Lavoue a,b,c,*, M. Redpath d, N. Bertheuil b,e, F. Foucher a,J.Lev^eque a,b,c a CHU de Rennes, Gynecology Department, Tertiary Surgery Center, Teaching Hospital of Rennes, Hopital^ Sud, 16, Bd de Bulgarie, 35000 Rennes, France b Universite de Rennes, Faculty of Medicine, 2 Henry Guilloux, 35000 Rennes, France c INSERM, ER440, Oncogenesis, Stress and Signaling (OSS), Rennes, France d McGill University, Department of Pathology, Jewish General Hospital, Cote^ Sainte Catherine, Montreal, QC, Canada e CHU de Rennes, Department of Plastic, Reconstructive and Aesthetic Surgery, Tertiary Surgery Center, Teaching Hospital of Rennes, Hopital^ Sud, 16, Bd de Bulgarie, 35000 Rennes, France Accepted 26 March 2015 Available online --- Abstract Objective: Pelvic exenteration requires complete resection of the tumor with negative margins to be considered a curative surgery. The pur- pose of this review is to assess the optimal preoperative evaluation and surgical approach in patients with recurrent cervical cancer to in- crease the chances of achieving a curative surgery with decreased morbidity and mortality in the era of concurrent chemoradiotherapy. Methods: Review of English publications pertaining to cervical cancer within the last 25 years were included using PubMed and Cochrane Library searches. Results: Modern imaging (MRI and PET-CT) does not accurately identify local extension of microscopic disease and is inadequate for pre- operative planning of extent of resection.
    [Show full text]
  • Pelvic Exenteration for the Management of Pelvic Malignancies
    Chapter 7 Pelvic Exenteration for the Management of Pelvic Malignancies Daniel Paramythiotis, Konstantinia Kofina and Antonios Michalopoulos Additional information is available at the end of the chapter http://dx.doi.org/10.5772/61083 Abstract Pelvic exenteration is a surgical procedure first described by Brunschwig in 1948 as a curative or palliative treatment for pelvic and perineal tumors. It is actually a radical operation, involving en bloc resection of pelvic organs, including reproductive structures, bladder, and rectosigmoid. In patients with recurrent cervical and vaginal malignancy, it is associated with a 5-year survival of more than 50%. In spite of advances in surgical management, consequences such as stomas, are still frequently unavoidable for radical tumor excision. Most candidates for this procedure have been diagnosed with recurrent cervical cancer that has previously been treated with surgery and radiation, or radiation alone. Complications of pelvic exenteration are more severe than those of standard resection of a colorectal carcinoma, so it is not commonly performed, including wound infection, wound dehiscence (also described as burst abdomen) the creation of fistulae (perineal-fecal, uretero-vaginal, between conduit and perineal wound), urinary tract infections, perineal hernias and intestinal obstruction. Patients need to be carefully selected and counseled about risks and long-term issues related to the surgery. A comprehensive evaluation is required in order to exclude unresectable or metastatic disease. Evolution of the technique through laparoscopy and minimally invasive surgery may result in a reduction of morbidity and mortality. Keywords: Pelvic exenteration, gynecologic cancer 1. Introduction Pelvic exenteration was first described by Brunschwig and his colleagues of New York’s Memorial Hospital in 1948 [1] and was initially performed as a palliative surgical intervention © 2015 The Author(s).
    [Show full text]
  • Treating Cervical Cancer If You've Been Diagnosed with Cervical Cancer, Your Cancer Care Team Will Talk with You About Treatment Options
    cancer.org | 1.800.227.2345 Treating Cervical Cancer If you've been diagnosed with cervical cancer, your cancer care team will talk with you about treatment options. In choosing your treatment plan, you and your cancer care team will also take into account your age, your overall health, and your personal preferences. How is cervical cancer treated? Common types of treatments for cervical cancer include: ● Surgery for Cervical Cancer ● Radiation Therapy for Cervical Cancer ● Chemotherapy for Cervical Cancer ● Targeted Therapy for Cervical Cancer ● Immunotherapy for Cervical Cancer Common treatment approaches Depending on the type and stage of your cancer, you may need more than one type of treatment. For the earliest stages of cervical cancer, either surgery or radiation combined with chemo may be used. For later stages, radiation combined with chemo is usually the main treatment. Chemo (by itself) is often used to treat advanced cervical cancer. ● Treatment Options for Cervical Cancer, by Stage Who treats cervical cancer? Doctors on your cancer treatment team may include: 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 ● A gynecologist: a doctor who treats diseases of the female reproductive system ● A gynecologic oncologist: a doctor who specializes in cancers of the female reproductive system who can perform surgery and prescribe chemotherapy and other medicines ● A radiation oncologist: a doctor who uses radiation to treat cancer ● A medical oncologist: a doctor who uses chemotherapy and other medicines to treat cancer Many other specialists may be involved in your care as well, including nurse practitioners, nurses, psychologists, social workers, rehabilitation specialists, and other health professionals.
    [Show full text]
  • Once in a Lifetime Procedures Code List 2019 Effective: 11/14/2010
    Policy Name: Once in a Lifetime Procedures Once in a Lifetime Procedures Code List 2019 Effective: 11/14/2010 Family Rhinectomy Code Description 30160 Rhinectomy; total Family Laryngectomy Code Description 31360 Laryngectomy; total, without radical neck dissection 31365 Laryngectomy; total, with radical neck dissection Family Pneumonectomy Code Description 32440 Removal of lung, pneumonectomy; Removal of lung, pneumonectomy; with resection of segment of trachea followed by 32442 broncho-tracheal anastomosis (sleeve pneumonectomy) 32445 Removal of lung, pneumonectomy; extrapleural Family Splenectomy Code Description 38100 Splenectomy; total (separate procedure) Splenectomy; total, en bloc for extensive disease, in conjunction with other procedure (List 38102 in addition to code for primary procedure) Family Glossectomy Code Description Glossectomy; complete or total, with or without tracheostomy, without radical neck 41140 dissection Glossectomy; complete or total, with or without tracheostomy, with unilateral radical neck 41145 dissection Family Uvulectomy Code Description 42140 Uvulectomy, excision of uvula Family Gastrectomy Code Description 43620 Gastrectomy, total; with esophagoenterostomy 43621 Gastrectomy, total; with Roux-en-Y reconstruction 43622 Gastrectomy, total; with formation of intestinal pouch, any type Family Colectomy Code Description 44150 Colectomy, total, abdominal, without proctectomy; with ileostomy or ileoproctostomy 44151 Colectomy, total, abdominal, without proctectomy; with continent ileostomy 44155 Colectomy,
    [Show full text]
  • Seer Program Code Manual
    THE SEER PROGRAM CODE MANUAL Revised Edition June 1992 CANCER STATISTICS BRANCH SURVEILLANCE PROGRAM DIVISION OF CANCER PREVENTION AND CONTROL NATIONAL CANCER INSTITUTE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE NATIONAL INSTITUTES OF HEALTH Effective Date: Cases Diagnosed January 1, 1992 The SEER Program Code Manual Revised Edition June 1992 Editors Jack Cunningham Lynn Ries Benjamin Hankey Jennifer Seiffert Barbara Lyles Evelyn Shambaugh Constance Percy Valerie Van Holten Acknowledgements The editors wish to acknowledge the assistance of Terry Swenson, Maureen Troublefield, Diane Licitra, and Jerome Felix of Information Management Services, Inc., in the preparation of the SEER Program Code Manual. The editors also wish to acknowledge the assistance of Dr. John Berg in preparation of the section on multiple primary determination for lymphatic and hematopoietic diseases. TABLE OF CONTENTS PREFACE TO THE REVISED EDITION ....................................... vii COMPUTER RECORD FORMAT ............................................ 1 INTRODUCTION AND GENERAL INSTRUCTIONS .............................. 5 REFERENCES .......................................................... 37 SEER CODE SUMMARY .................................................. 39 I BASIC RECORD IDENTIFICATION ...................................... 57 1.01 SEER Participant ........................................... 58 1.02 Case Number .............................................. 59 1.03 Record Number ............................................ 60
    [Show full text]
  • Primary Pelvic Exenteration: Our Experience with 23 Patients from a Single Institution
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 22: 1060, 2021 Primary pelvic exenteration: Our experience with 23 patients from a single institution MIHAI GHEORGHE1, ALEXANDRA LAVINIA COZLEA1, SZILARD LEO KISS1, MIHAI STANCA1, MIHAI EMIL CĂPÎLNA1, NICOLAE BACALBAȘA2 and ANDREEA ANAMARIA MOLDOVAN3 1First Obstetrics and Gynecology Clinic, ‘George Emil Palade’ University of Medicine, Pharmacy, Science and Technology, 540136 Târgu Mureș; 2Department of Obstetrics and Gynecology, ‘Carol Davila’ University of Medicine and Pharmacy, 020022 Bucharest; 3Department of Infectious Diseases, Brașov County Emergency Hospital, 500326 Brașov, Romania Received May 24, 2021; Accepted June 23, 2021 DOI: 10.3892/etm.2021.10494 Abstract. This study was designed with an aim to share our Introduction experience of primary pelvic exenterations. The study included 23 patients with different types of pelvic cancer enrolled at a In patients with advanced primary or recurrent gyneco‑ single institution between November 2011 and July 2020. The logic (1), urologic or rectal cancers without metastatic disease, patient mean age was 55 years (range, 43‑72 years) and the extensive aggressive surgery such as pelvic exenteration may oncological indications included: Stage IVa cervical cancer be necessary for curative intent treatment (2). (11 cases, 48.9%), stage IVa endometrial cancer (1 case, 4.3%), Brunschwig was the first to describe pelvic exentera‑ stage IVa vaginal cancer (6 cases, 26%), stage IIIb bladder tion in the 1940s (3). Exenteration was initially considered cancer (3 cases, 13%), stage IIIc rectal cancer (1 case, 4.3%) as a palliative procedure for patients with extensive pelvic and undifferentiated pelvic sarcoma (1 case, 4.3%). Total, cancers, with an extremely high perioperative mortality rate anterior, and posterior pelvic exenterations were performed of 23%.
    [Show full text]
  • Introduction to Pelvic Obstetric and Gynaecology Physiotherapy
    INTRODUCTION TO PELVIC OBSTETRIC AND GYNAECOLOGY PHYSIOTHERAPY An Educational Resource Published by the Pelvic, Obstetric and Gynaecology Physiotherapy Contact: POGP Administration, Fitwise Management Ltd., Drumcross Hall, Bathgate, West Lothian EH48 4JT T: 01506 811077 E: [email protected] or visit the POGP website www.pogp.org.uk for further information. ©POGP 2015 for review 2018 Contents CCCCC Introduction .........................................................................................................3 Core skill framework.............................................................................................4 Obstetrics..............................................................................................................5 Urology, Gynaecology and Colorectal..................................................................8 Breast Oncology……………………………………………………..………...………………..….……..17 Appendices 1. Obstetric abbreviations ..........................................................................19 2. Obstetric terminology ............................................................................20 3. Urology/ Gynaecology terminology……………………………………..……………..26 4. Gynaecology surgery terminology…………………………………………..………....29 5. Colorectal terminology…………………………………………………..………………..…31 6. Advanced clinical objectives for performing internal examinations…….34 C o n t e n t s 1 T H R E Introduction It is acknowledged that physiotherapists may become involved in the management of pelvic, obstetric and gynaecology patients
    [Show full text]
  • OBGYN Outpatient Surgery Coding
    OBGYN Outpatient Surgery Coding Anatomy Anatomy • Hyster/o – uterus, womb • Uter/o – uterus, womb • Metr/o – uterus, womb • Salping/o – tube, usually fallopian tube • Oophor/o – ovary • Ovari/o - ovary Terminology • Colpo – vagina • Cervic/o – cervix, lower part of the uterus, the “neck” • Episi/o – vulva • Vulv/o – vulva • Perine/o – the space between the anus and vulva Hysterectomy • A hysterectomy is an operation to remove a woman's uterus. • A woman may have a hysterectomy for different reasons, including: • Uterine fibroids that cause pain • bleeding, or other problems. • Uterine prolapse, which is a sliding of the uterus from its normal position into the vaginal canal. Hysterectomy • There are around 30 hysterectomy CPT codes. • To find the correct code you have to first check: • the surgical approach and • extent of the procedure. Surgical Approaches • Abdominal – the uterus is removed via an incision in the lower abdomen • Vaginal – the uterus is removed via an incision in the vagina • Laparoscopic – the procedure is performed using a laparoscope , inserted via several small incisions in the body. • Their are also CPT codes for laparoscopic-assisted vaginal approach. In this procedure ,the scope is inserted via a small incisions in the vagina. Extent of Procedure • Total hysterectomy: It includes laparoscopically detaching the entire uterine cervix and body from the surrounding supporting structures and suturing the vaginal cuff. It includes bivalving, coring, or morcellating the excised tissues, as required. The uterus is then removed through the vagina or abdomen. • Subtotal, partial or supracervical hysterectomy: It is the removal of the fundus or op portion of the uterus only, leaving the cervix in place.
    [Show full text]
  • 2015 Colorectal Surgery Medicare Reimbursement Coding Guide Effective January 1, 2015
    2015 Colorectal Surgery Medicare Reimbursement Coding Guide Effective January 1, 2015 MEDICARE NATIONAL AVERAGE RATES AND ALLOWABLES (NOT ADJUSTED FOR GEOGRAPHY) AMBULATORY Physician HOSPITAL OUPATIENT SURGICAL CENTER CPT™* *MPFS APC APC **APC HCPCS Procedure Description (CF=$35.7547) ***ASC Classification Descriptor Rate Code Fac/Non-Fac COLECTOMY 44140 Colectomy, partial; with anastomosis $1,388.36 Inpatient Procedures, not reimbursed in outpatient or ASC by Medicare 44141 Colectomy, partial; with skin level cecostomy or colostomy $1,888.92 Inpatient Procedures, not reimbursed in outpatient or ASC by Medicare Colectomy, partial; with end colostomy and closure of distal 44143 Inpatient Procedures, not reimbursed in outpatient or ASC by Medicare segment (Hartmann type procedure) $1,723.02 Colectomy, partial; with resection, with colostomy or 44144 Inpatient Procedures, not reimbursed in outpatient or ASC by Medicare ileostomy and creation of mucofistula $1,832.43 Colectomy, partial; with coloproctostomy (low pelvic 44145 Inpatient Procedures, not reimbursed in outpatient or ASC by Medicare anastomosis) $1,716.23 Colectomy, partial; with coloproctostomy (low pelvic 44146 Inpatient Procedures, not reimbursed in outpatient or ASC by Medicare anastomosis), with colostomy $2,197.84 44147 Colectomy, partial; abdominal and transanal approach $2,013.35 Inpatient Procedures, not reimbursed in outpatient or ASC by Medicare Colectomy, total, abdominal, without proctectomy; with 44150 Inpatient Procedures, not reimbursed in outpatient or ASC by Medicare
    [Show full text]
  • SJH Procedures
    SJH Procedures - Gynecology and Gynecology Oncology Services New Name Old Name CPT Code Service ABLATION, LESION, CERVIX AND VULVA, USING CO2 LASER LASER VAPORIZATION CERVIX/VULVA W CO2 LASER 56501 Destruction of lesion(s), vulva; simple (eg, laser surgery, Gynecology electrosurgery, cryosurgery, chemosurgery) 56515 Destruction of lesion(s), vulva; extensive (eg, laser surgery, Gynecology electrosurgery, cryosurgery, chemosurgery) 57513 Cautery of cervix; laser ablation Gynecology BIOPSY OR EXCISION, LESION, FACE AND NECK EXCISION/BIOPSY (MASS/LESION/LIPOMA/CYST) FACE/NECK General, Gynecology, Plastics, ENT, Maxillofacial BIOPSY OR EXCISION, LESION, FACE AND NECK, 2 OR MORE EXCISE/BIOPSY (MASS/LESION/LIPOMA/CYST) MULTIPLE FACE/NECK 11102 Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); General, Gynecology, single lesion Aesthetics, Urology, Maxillofacial, ENT, Thoracic, Vascular, Cardiovascular, Plastics, Orthopedics 11103 Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); General, Gynecology, each separate/additional lesion (list separately in addition to Aesthetics, Urology, code for primary procedure) Maxillofacial, ENT, Thoracic, Vascular, Cardiovascular, Plastics, Orthopedics 11104 Punch biopsy of skin (including simple closure, when General, Gynecology, performed); single lesion Aesthetics, Urology, Maxillofacial, ENT, Thoracic, Vascular, Cardiovascular, Plastics, Orthopedics 11105 Punch biopsy of skin (including simple closure, when General, Gynecology, performed); each separate/additional lesion
    [Show full text]
  • FY 2009 Final Addenda ICD-9-CM Volume 3, Procedures Effective October 1, 2008
    FY 2009 Final Addenda ICD-9-CM Volume 3, Procedures Effective October 1, 2008 Tabular 00.3 Computer assisted surgery [CAS] Add inclusion term That without the use of robotic(s) technology Add exclusion term Excludes: robotic assisted procedures (17.41-17.49) New code 00.49 SuperSaturated oxygen therapy Aqueous oxygen (AO) therapy SSO2 SuperOxygenation infusion therapy Code also any: injection or infusion of thrombolytic agent (99.10) insertion of coronary artery stent(s) (36.06-36.07) intracoronary artery thrombolytic infusion (36.04) number of vascular stents inserted (00.45-00.48) number of vessels treated (00.40-00.43) open chest coronary artery angioplasty (36.03) other removal of coronary obstruction (36.09) percutaneous transluminal coronary angioplasty [PTCA] (00.66) procedure on vessel bifurcation (00.44) Excludes: other oxygen enrichment (93.96) other perfusion (39.97) New Code 00.58 Insertion of intra-aneurysm sac pressure monitoring device (intraoperative) Insertion of pressure sensor during endovascular repair of abdominal or thoracic aortic aneurysm(s) New code 00.59 Intravascular pressure measurement of coronary arteries Includes: fractional flow reserve (FFR) Code also any synchronous diagnostic or therapeutic procedures Excludes: intravascular pressure measurement of intrathoracic arteries (00.67) 00.66 Percutaneous transluminal coronary angioplasty [PTCA] or coronary atherectomy Add code also note Code also any: SuperSaturated oxygen therapy (00.49) 1 New code 00.67 Intravascular pressure measurement of intrathoracic
    [Show full text]
  • Intestinal Vaginoplasty: Which Should Be the Bowel Segment of Choice?
    Academic Year 2014 – 2015 INTESTINAL VAGINOPLASTY: WHICH SHOULD BE THE BOWEL SEGMENT OF CHOICE? Cedric ROBBENS Promotor: Prof. Dr. Stan Monstrey Dissertation presented in the 2nd Master year in the programme of Master of Medicine in Medicine Deze pagina is niet beschikbaar omdat ze persoonsgegevens bevat. Universiteitsbibliotheek Gent, 2021. This page is not available because it contains personal information. Ghent Universit , Librar , 2021. Deze pagina is niet beschikbaar omdat ze persoonsgegevens bevat. Universiteitsbibliotheek Gent, 2021. This page is not available because it contains personal information. Ghent Universit , Librar , 2021. PREFACE My thesis discusses the use of bowel segments in vaginoplasty. I have chosen this subject because of my interest in reconstructive surgery. I am very grateful for the opportunity to write this work about a topic in my field of interest. I would like to thank all the people that helped bringing this literature review to a successful conclusion. First of all, the promotor of this literature review Prof. Dr. Stan Monstrey for the guidance and the counseling. My parents, Frank Robbens and Karine De Saedeleir, for giving me the chance to study and always supporting me. And finally, my sister Evy Robbens for revising this work. I end this preface with a quote by Walt Whitman (1819 – 1892) that represents the fundamental idea of this assignment: “That the powerful play goes on and you may contribute a verse. What will your verse be?” Cedric Robbens 08.04.2015 TABLE OF CONTENTS FRONT COVER TITLE PAGE
    [Show full text]